SciVision Biotech Inc

SciVision Biotech Inc maintains a strong liquidity position, with a current ratio of 8.17 and cash and equivalents amounting to TWD 845.35 million, which is significantly higher than the industry median. The company's debt-to-equity ratio of 0.24 indicates a conservative capital structure, with long-term debt of TWD 485.13 million compared to total equity of TWD 1.98 billion. In terms of profitability, SciVision Biotech Inc reports a return on equity (ROE) of 8.2% and a return on assets (ROA) of 6.08%, which are in line with the industry's preferred metrics. The company's gross profit of TWD 638.39 million and operating income of TWD 189.92 million reflect a healthy margin structure, although the net income of TWD 162.34 million suggests some operational inefficiencies or expenses. The company's revenue is distributed across multiple geographic regions, including the Americas, Europe, Asia, the Middle East, and Africa. However, the financial snapshot does not provide specific revenue concentrations by segment or region, making it difficult to assess the extent of geographic diversification. SciVision Biotech Inc's growth trajectory is supported by a positive outlook, with the current fiscal year (FY) expected to show continued revenue growth. The company's free cash flow, although negative at TWD -92.63 million, is offset by a strong operating cash flow of TWD 123.99 million, indicating the company's ability to generate cash from operations. The risk assessment for SciVision Biotech Inc indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital expenditure of TWD -101.53 million suggests ongoing investment in its operations, which could support future growth. Recent events and filings do not indicate any significant changes in the company's operations or financial status. The company's last actual EPS was TWD 2.18, and the last actual revenue was TWD 886.62 million, aligning with the financial snapshot.